Company: PTHS
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001753926-25-001326
Chunk: 61

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 61
---
 of Common Stock, (D) principal in the amount of $197,421,
along with accrued interest of $8,169 as of February 21, 2024, outstanding under our senior secured convertible notes issued in
the September Bridge Financing (after giving effect to the Representative Affiliate Transactions), automatically converted into
approximately 4,339 shares of Common Stock, which includes an additional 55 Bonus Shares issuable as consideration for the September
Bridge Financing, (E) we issued 3,750 shares of Common Stock to an investor as consideration for its previous agreement to provide
funding that is no longer necessary in connection with the IPO, (F) we effected the Representative Affiliate Transactions, (G)
we effected the transactions contemplated by the Holdings Side Letter, and issued an aggregate of 2,600 shares of Series C Preferred
Stock to Chromocell Holdings pursuant thereto, and (H) we issued (i) 9,383 shares to a lender holding the Investor Note and (ii)
2,917 shares to one of our directors holding the Director Note in full satisfaction of our obligations thereunder (in the case
of (A) through (D) and (H) above, based on the IPO price of $60.00 per IPO Share).

In
addition, certain Selling Stockholders, as identified in the Registration Statement, have agreed to offer for resale of up to
an aggregate of 296,983 Selling Stockholder Shares to the public. After conversion of the convertible notes or shares of preferred
stock, as applicable, the Selling Stockholders, or their respective transferees, pledgees, donees or other successors-in-interest,
may sell the Selling Stockholders Shares through public or private transactions at prevailing market prices, at prices related
to prevailing market prices or at privately negotiated prices. We will not receive any proceeds from the sale of the Stockholder
Shares by the Selling Stockholders.

39 

On
July 26, 2024, the Company entered into a Common Stock Purchase Agreement, dated as of July 26, 2024 (the “CEF Purchase
Agreement”), with Tikkun Capital LLC (“Tikkun”), providing for a committed equity financing facility, pursuant
to which, upon the terms and subject to the satisfaction of the conditions contained in the CEF Purchase Agreement, Tikkun has
committed to purchase, at the Company’s direction in its sole discretion, up to an aggregate of $30,000,000 (the “Total